Comparative cutoff points for adenosine monophosphate and methacholine challenge testing

Current use of the PC 20 (provocation concentration that causes a decrease in forced expiratory volume in 1 second of 20%) cutoff point for bronchial challenge precludes its use in patients with more severe airflow obstruction. To evaluate the efficacy and safety of lower cutoff points for adenosine...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of allergy, asthma, & immunology asthma, & immunology, 2004-10, Vol.93 (4), p.365-372
Hauptverfasser: Fardon, Tom C., Fardon, Emma J., Hodge, Melissa R., Lipworth, Brian J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 372
container_issue 4
container_start_page 365
container_title Annals of allergy, asthma, & immunology
container_volume 93
creator Fardon, Tom C.
Fardon, Emma J.
Hodge, Melissa R.
Lipworth, Brian J.
description Current use of the PC 20 (provocation concentration that causes a decrease in forced expiratory volume in 1 second of 20%) cutoff point for bronchial challenge precludes its use in patients with more severe airflow obstruction. To evaluate the efficacy and safety of lower cutoff points for adenosine monophosphate (AMP) and methacholine (MCH) bronchial challenge tools to monitor response to treatment in chronic asthma. We retrospectively examined data from 5 previously published studies (2 using AMP, 2 using MCH, and 1 with MCH and AMP arms) and recalculated 10% and 15% cutoff points for AMP and MCH. Data were analyzed for correlation of single results and doubling dose shifts after anti-inflammatory treatment intervention. A total of 175 individual MCH challenges and 152 AMP challenges were evaluated. Evaluating the doubling dose shift produced by the addition of anti-inflammatory treatment (inhaled corticosteroids or montelukast) produced the following Pearson correlation coefficients: MCH PD 20 (provocation dose that causes a decrease in forced expiratory volume in 1 second of 20%) vs PD 15, 0.80; MCH PD 20 vs PD 10, 0.65; AMP PC 20 vs PC 15, 0.96; and AMP PC 20 vs PC 10, 0.84 ( P < .001 for all). Subgroup analysis of AMP for before and after inhaled corticosteroids only (n = 41) shows AMP PC 20 vs PC 15 of 0.92 and AMP PC 20 vs PC 10 of 0.84 ( P < .001 for both). The 10% and 15% cutoff points strongly predict the 20% cutoff value for AMP and MCH, as do the doubling dose shifts after anti-inflammatory treatment. The lower thresholds are suitable for monitoring response to therapy, and they expose patients to significantly less provocation agent.
doi_str_mv 10.1016/S1081-1206(10)61396-8
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67033869</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1081120610613968</els_id><sourcerecordid>67033869</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-b80d5c7f06960a8baad65347f6c718a924ff1128d3843b568b068bb3f6db88633</originalsourceid><addsrcrecordid>eNqFkE2L1TAUhoMozjj6E5QiKLqo5jRtmq5ELn7BgAsV3IU0OZlmaJOapAP-e9O5VwbcuAgJyXNO3vMQ8hToG6DA334DKqCGhvJXQF9zYAOvxT1yDh1r67Zl_H45_0XOyKOUrimlIDh7SM6g6xpgPTsnPw9hWVVU2d1gpbccrK3W4HxOlQ2xUgZ9SM5jtQQf1imkdVIZK-VNtWCelJ7CvD_rSc0z-iusMqbs_NVj8sCqOeGT035Bfnz88P3wub78-unL4f1lrVsQuR4FNZ3uLeUDp0qMShleJugt1z0INTSttQCNMEy0bOy4GGlZI7PcjKIMwy7Iy2PfNYZfW_lbLi5pnGflMWxJ8p4yJvhQwOf_gNdhi75kkw1teiGooAXqjpCOIaWIVq7RLSr-lkDl7l3eepe71P3q1rsUpe7Zqfk2Lmjuqk6iC_DiBKik1Wyj8tqlO443MDTdnvLdkcPi7MZhlEk79BqNi6izNMH9J8ofRf6fNA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>202788080</pqid></control><display><type>article</type><title>Comparative cutoff points for adenosine monophosphate and methacholine challenge testing</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Fardon, Tom C. ; Fardon, Emma J. ; Hodge, Melissa R. ; Lipworth, Brian J.</creator><creatorcontrib>Fardon, Tom C. ; Fardon, Emma J. ; Hodge, Melissa R. ; Lipworth, Brian J.</creatorcontrib><description>Current use of the PC 20 (provocation concentration that causes a decrease in forced expiratory volume in 1 second of 20%) cutoff point for bronchial challenge precludes its use in patients with more severe airflow obstruction. To evaluate the efficacy and safety of lower cutoff points for adenosine monophosphate (AMP) and methacholine (MCH) bronchial challenge tools to monitor response to treatment in chronic asthma. We retrospectively examined data from 5 previously published studies (2 using AMP, 2 using MCH, and 1 with MCH and AMP arms) and recalculated 10% and 15% cutoff points for AMP and MCH. Data were analyzed for correlation of single results and doubling dose shifts after anti-inflammatory treatment intervention. A total of 175 individual MCH challenges and 152 AMP challenges were evaluated. Evaluating the doubling dose shift produced by the addition of anti-inflammatory treatment (inhaled corticosteroids or montelukast) produced the following Pearson correlation coefficients: MCH PD 20 (provocation dose that causes a decrease in forced expiratory volume in 1 second of 20%) vs PD 15, 0.80; MCH PD 20 vs PD 10, 0.65; AMP PC 20 vs PC 15, 0.96; and AMP PC 20 vs PC 10, 0.84 ( P &lt; .001 for all). Subgroup analysis of AMP for before and after inhaled corticosteroids only (n = 41) shows AMP PC 20 vs PC 15 of 0.92 and AMP PC 20 vs PC 10 of 0.84 ( P &lt; .001 for both). The 10% and 15% cutoff points strongly predict the 20% cutoff value for AMP and MCH, as do the doubling dose shifts after anti-inflammatory treatment. The lower thresholds are suitable for monitoring response to therapy, and they expose patients to significantly less provocation agent.</description><identifier>ISSN: 1081-1206</identifier><identifier>EISSN: 1534-4436</identifier><identifier>DOI: 10.1016/S1081-1206(10)61396-8</identifier><identifier>PMID: 15521373</identifier><identifier>CODEN: ANAEA3</identifier><language>eng</language><publisher>McLean, VA: Elsevier Inc</publisher><subject><![CDATA[Acetates - administration & dosage ; Acetates - therapeutic use ; Adenosine Monophosphate - administration & dosage ; Administration, Inhalation ; Adrenal Cortex Hormones - administration & dosage ; Adrenal Cortex Hormones - therapeutic use ; Anti-Asthmatic Agents - administration & dosage ; Anti-Asthmatic Agents - therapeutic use ; Asthma - drug therapy ; Biological and medical sciences ; Bronchial Hyperreactivity - drug therapy ; Bronchial Provocation Tests - methods ; Bronchial Provocation Tests - standards ; Bronchoconstrictor Agents - administration & dosage ; Forced Expiratory Volume ; Humans ; Immunopathology ; Medical sciences ; Methacholine Chloride - administration & dosage ; Quinolines - administration & dosage ; Quinolines - therapeutic use ; Retrospective Studies]]></subject><ispartof>Annals of allergy, asthma, &amp; immunology, 2004-10, Vol.93 (4), p.365-372</ispartof><rights>2004 American College of Allergy, Asthma &amp; Immunology</rights><rights>2004 INIST-CNRS</rights><rights>Copyright American College of Allergy and Immunology Oct 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-b80d5c7f06960a8baad65347f6c718a924ff1128d3843b568b068bb3f6db88633</citedby><cites>FETCH-LOGICAL-c418t-b80d5c7f06960a8baad65347f6c718a924ff1128d3843b568b068bb3f6db88633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S1081-1206(10)61396-8$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16219259$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15521373$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fardon, Tom C.</creatorcontrib><creatorcontrib>Fardon, Emma J.</creatorcontrib><creatorcontrib>Hodge, Melissa R.</creatorcontrib><creatorcontrib>Lipworth, Brian J.</creatorcontrib><title>Comparative cutoff points for adenosine monophosphate and methacholine challenge testing</title><title>Annals of allergy, asthma, &amp; immunology</title><addtitle>Ann Allergy Asthma Immunol</addtitle><description>Current use of the PC 20 (provocation concentration that causes a decrease in forced expiratory volume in 1 second of 20%) cutoff point for bronchial challenge precludes its use in patients with more severe airflow obstruction. To evaluate the efficacy and safety of lower cutoff points for adenosine monophosphate (AMP) and methacholine (MCH) bronchial challenge tools to monitor response to treatment in chronic asthma. We retrospectively examined data from 5 previously published studies (2 using AMP, 2 using MCH, and 1 with MCH and AMP arms) and recalculated 10% and 15% cutoff points for AMP and MCH. Data were analyzed for correlation of single results and doubling dose shifts after anti-inflammatory treatment intervention. A total of 175 individual MCH challenges and 152 AMP challenges were evaluated. Evaluating the doubling dose shift produced by the addition of anti-inflammatory treatment (inhaled corticosteroids or montelukast) produced the following Pearson correlation coefficients: MCH PD 20 (provocation dose that causes a decrease in forced expiratory volume in 1 second of 20%) vs PD 15, 0.80; MCH PD 20 vs PD 10, 0.65; AMP PC 20 vs PC 15, 0.96; and AMP PC 20 vs PC 10, 0.84 ( P &lt; .001 for all). Subgroup analysis of AMP for before and after inhaled corticosteroids only (n = 41) shows AMP PC 20 vs PC 15 of 0.92 and AMP PC 20 vs PC 10 of 0.84 ( P &lt; .001 for both). The 10% and 15% cutoff points strongly predict the 20% cutoff value for AMP and MCH, as do the doubling dose shifts after anti-inflammatory treatment. The lower thresholds are suitable for monitoring response to therapy, and they expose patients to significantly less provocation agent.</description><subject>Acetates - administration &amp; dosage</subject><subject>Acetates - therapeutic use</subject><subject>Adenosine Monophosphate - administration &amp; dosage</subject><subject>Administration, Inhalation</subject><subject>Adrenal Cortex Hormones - administration &amp; dosage</subject><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Anti-Asthmatic Agents - administration &amp; dosage</subject><subject>Anti-Asthmatic Agents - therapeutic use</subject><subject>Asthma - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Bronchial Hyperreactivity - drug therapy</subject><subject>Bronchial Provocation Tests - methods</subject><subject>Bronchial Provocation Tests - standards</subject><subject>Bronchoconstrictor Agents - administration &amp; dosage</subject><subject>Forced Expiratory Volume</subject><subject>Humans</subject><subject>Immunopathology</subject><subject>Medical sciences</subject><subject>Methacholine Chloride - administration &amp; dosage</subject><subject>Quinolines - administration &amp; dosage</subject><subject>Quinolines - therapeutic use</subject><subject>Retrospective Studies</subject><issn>1081-1206</issn><issn>1534-4436</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE2L1TAUhoMozjj6E5QiKLqo5jRtmq5ELn7BgAsV3IU0OZlmaJOapAP-e9O5VwbcuAgJyXNO3vMQ8hToG6DA334DKqCGhvJXQF9zYAOvxT1yDh1r67Zl_H45_0XOyKOUrimlIDh7SM6g6xpgPTsnPw9hWVVU2d1gpbccrK3W4HxOlQ2xUgZ9SM5jtQQf1imkdVIZK-VNtWCelJ7CvD_rSc0z-iusMqbs_NVj8sCqOeGT035Bfnz88P3wub78-unL4f1lrVsQuR4FNZ3uLeUDp0qMShleJugt1z0INTSttQCNMEy0bOy4GGlZI7PcjKIMwy7Iy2PfNYZfW_lbLi5pnGflMWxJ8p4yJvhQwOf_gNdhi75kkw1teiGooAXqjpCOIaWIVq7RLSr-lkDl7l3eepe71P3q1rsUpe7Zqfk2Lmjuqk6iC_DiBKik1Wyj8tqlO443MDTdnvLdkcPi7MZhlEk79BqNi6izNMH9J8ofRf6fNA</recordid><startdate>20041001</startdate><enddate>20041001</enddate><creator>Fardon, Tom C.</creator><creator>Fardon, Emma J.</creator><creator>Hodge, Melissa R.</creator><creator>Lipworth, Brian J.</creator><general>Elsevier Inc</general><general>American College of Allergy, Asthma, &amp; Immunology</general><general>American College of Allergy and Immunology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20041001</creationdate><title>Comparative cutoff points for adenosine monophosphate and methacholine challenge testing</title><author>Fardon, Tom C. ; Fardon, Emma J. ; Hodge, Melissa R. ; Lipworth, Brian J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-b80d5c7f06960a8baad65347f6c718a924ff1128d3843b568b068bb3f6db88633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Acetates - administration &amp; dosage</topic><topic>Acetates - therapeutic use</topic><topic>Adenosine Monophosphate - administration &amp; dosage</topic><topic>Administration, Inhalation</topic><topic>Adrenal Cortex Hormones - administration &amp; dosage</topic><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Anti-Asthmatic Agents - administration &amp; dosage</topic><topic>Anti-Asthmatic Agents - therapeutic use</topic><topic>Asthma - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Bronchial Hyperreactivity - drug therapy</topic><topic>Bronchial Provocation Tests - methods</topic><topic>Bronchial Provocation Tests - standards</topic><topic>Bronchoconstrictor Agents - administration &amp; dosage</topic><topic>Forced Expiratory Volume</topic><topic>Humans</topic><topic>Immunopathology</topic><topic>Medical sciences</topic><topic>Methacholine Chloride - administration &amp; dosage</topic><topic>Quinolines - administration &amp; dosage</topic><topic>Quinolines - therapeutic use</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fardon, Tom C.</creatorcontrib><creatorcontrib>Fardon, Emma J.</creatorcontrib><creatorcontrib>Hodge, Melissa R.</creatorcontrib><creatorcontrib>Lipworth, Brian J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of allergy, asthma, &amp; immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fardon, Tom C.</au><au>Fardon, Emma J.</au><au>Hodge, Melissa R.</au><au>Lipworth, Brian J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative cutoff points for adenosine monophosphate and methacholine challenge testing</atitle><jtitle>Annals of allergy, asthma, &amp; immunology</jtitle><addtitle>Ann Allergy Asthma Immunol</addtitle><date>2004-10-01</date><risdate>2004</risdate><volume>93</volume><issue>4</issue><spage>365</spage><epage>372</epage><pages>365-372</pages><issn>1081-1206</issn><eissn>1534-4436</eissn><coden>ANAEA3</coden><abstract>Current use of the PC 20 (provocation concentration that causes a decrease in forced expiratory volume in 1 second of 20%) cutoff point for bronchial challenge precludes its use in patients with more severe airflow obstruction. To evaluate the efficacy and safety of lower cutoff points for adenosine monophosphate (AMP) and methacholine (MCH) bronchial challenge tools to monitor response to treatment in chronic asthma. We retrospectively examined data from 5 previously published studies (2 using AMP, 2 using MCH, and 1 with MCH and AMP arms) and recalculated 10% and 15% cutoff points for AMP and MCH. Data were analyzed for correlation of single results and doubling dose shifts after anti-inflammatory treatment intervention. A total of 175 individual MCH challenges and 152 AMP challenges were evaluated. Evaluating the doubling dose shift produced by the addition of anti-inflammatory treatment (inhaled corticosteroids or montelukast) produced the following Pearson correlation coefficients: MCH PD 20 (provocation dose that causes a decrease in forced expiratory volume in 1 second of 20%) vs PD 15, 0.80; MCH PD 20 vs PD 10, 0.65; AMP PC 20 vs PC 15, 0.96; and AMP PC 20 vs PC 10, 0.84 ( P &lt; .001 for all). Subgroup analysis of AMP for before and after inhaled corticosteroids only (n = 41) shows AMP PC 20 vs PC 15 of 0.92 and AMP PC 20 vs PC 10 of 0.84 ( P &lt; .001 for both). The 10% and 15% cutoff points strongly predict the 20% cutoff value for AMP and MCH, as do the doubling dose shifts after anti-inflammatory treatment. The lower thresholds are suitable for monitoring response to therapy, and they expose patients to significantly less provocation agent.</abstract><cop>McLean, VA</cop><pub>Elsevier Inc</pub><pmid>15521373</pmid><doi>10.1016/S1081-1206(10)61396-8</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1081-1206
ispartof Annals of allergy, asthma, & immunology, 2004-10, Vol.93 (4), p.365-372
issn 1081-1206
1534-4436
language eng
recordid cdi_proquest_miscellaneous_67033869
source MEDLINE; Elsevier ScienceDirect Journals
subjects Acetates - administration & dosage
Acetates - therapeutic use
Adenosine Monophosphate - administration & dosage
Administration, Inhalation
Adrenal Cortex Hormones - administration & dosage
Adrenal Cortex Hormones - therapeutic use
Anti-Asthmatic Agents - administration & dosage
Anti-Asthmatic Agents - therapeutic use
Asthma - drug therapy
Biological and medical sciences
Bronchial Hyperreactivity - drug therapy
Bronchial Provocation Tests - methods
Bronchial Provocation Tests - standards
Bronchoconstrictor Agents - administration & dosage
Forced Expiratory Volume
Humans
Immunopathology
Medical sciences
Methacholine Chloride - administration & dosage
Quinolines - administration & dosage
Quinolines - therapeutic use
Retrospective Studies
title Comparative cutoff points for adenosine monophosphate and methacholine challenge testing
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T19%3A53%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20cutoff%20points%20for%20adenosine%20monophosphate%20and%20methacholine%20challenge%20testing&rft.jtitle=Annals%20of%20allergy,%20asthma,%20&%20immunology&rft.au=Fardon,%20Tom%20C.&rft.date=2004-10-01&rft.volume=93&rft.issue=4&rft.spage=365&rft.epage=372&rft.pages=365-372&rft.issn=1081-1206&rft.eissn=1534-4436&rft.coden=ANAEA3&rft_id=info:doi/10.1016/S1081-1206(10)61396-8&rft_dat=%3Cproquest_cross%3E67033869%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=202788080&rft_id=info:pmid/15521373&rft_els_id=S1081120610613968&rfr_iscdi=true